Roche Expects Better Xofluza Sales After New Indication
Executive SummaryFlu treatment is newly approved for patients at higher risk of flu complications, and Roche is studying other patient groups that could help expand its potential market.
You may also be interested in...
The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.